Skip to main content
Myo Htut, MD, Oncology, Duarte, CA

MyoHtutMD

Oncology Duarte, CA

Hematologic Oncology

Physician

Overview of Dr. Htut

Dr. Myo Htut is an oncologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from University Institute of Medicine 1 and has been in practice 21 years. He is one of 220 doctors at City of Hope Comprehensive Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2009
  • MedStar Health/Harbor Hospital
    MedStar Health/Harbor HospitalResidency, Internal Medicine, 1999 - 2002
  • University Institute of Medicine 1
    University Institute of Medicine 1Class of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2002 - 2025
  • CO State Medical License
    CO State Medical License 2008 - 2011
  • MI State Medical License
    MI State Medical License 2002 - 2009
  • PA State Medical License
    PA State Medical License 2004 - 2006
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
    Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

  • Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Myo Htut, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • CD84: A Potential Novel Therapeutic Target in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative Neoplasm
    OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
  • Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH Meeting
    Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH MeetingDecember 2nd, 2016